-
Je něco špatně v tomto záznamu ?
Therapeutic influence of 20 % albumin versus 6% hydroxyethylstarch on extravascular lung water in septic patients: a randomized controlled trial
M. Dolecek, P. Svoboda, I. Kantorova, P. Scheer, I. Sas, J. Bibrova, J. Radvanova, M. Radvan
Jazyk angličtina Země Řecko
Typ dokumentu srovnávací studie, randomizované kontrolované studie, práce podpořená grantem
Grantová podpora
NR8561
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
- MeSH
- albuminy aplikace a dávkování MeSH
- deriváty hydroxyethylového škrobu aplikace a dávkování MeSH
- dospělí MeSH
- extravaskulární plicní voda účinky léků MeSH
- kapilární permeabilita MeSH
- kyslík krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- plíce patofyziologie MeSH
- plicní edém prevence a kontrola MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sepse parazitologie terapie MeSH
- sérový albumin analýza MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
BACKGROUND/AIMS: Recent studies demonstrated that extravascular lung water (EVLW) is a reliable and independent marker for outcome. The primary therapeutically goal in critically ill patients is to resuscitate and retain adequate organ perfusion by fluid administration, where is necessary to achieve adequate intravascular filling, but avoid initiation of pulmonary edema. METHODOLOGY: Patients with severe sepsis were randomly allocated to a group treated with 20% Albumin 100 ml every 12 hours (ALB; n = 30) or with 6% hydroxyethylstarch 130/0, 4 250 ml every 6 hours (HES; n = 26). Both treatments were completed by crystalloids or norephinephrin as necessary. We analyzed amount of developed EVLW, and relation with mortality, PaO2/FiO2 and alveolo-arterial oxygen difference. RESULTS: We observed significantly greater decrease of EVLW when compared with baseline during whole monitored period of 72 hours in ALB group in contrast to HES patients (p < 0.05). Despite no significant changes of EVLW in HES group, we noted improve of PaO2/FiO2 and AaDO2 in both groups. We did not observed significant difference in mortality. CONCLUSION: The present study results show can summarize that albumin reduces in a higher amount and earlier the extravascular lung water than HES, but this reduction was not associated with improvement of oxygenation functions, which was better in HES group.
- 000
- 03210naa a2200529 a 4500
- 001
- bmc12008619
- 003
- CZ-PrNML
- 005
- 20140519142758.0
- 008
- 120316s2009 gr eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $d ABA008
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Doleček, Martin $7 xx0060606 $u Trauma Hospital Brno, Czech Republic.
- 245 10
- $a Therapeutic influence of 20 % albumin versus 6% hydroxyethylstarch on extravascular lung water in septic patients: a randomized controlled trial / $c M. Dolecek, P. Svoboda, I. Kantorova, P. Scheer, I. Sas, J. Bibrova, J. Radvanova, M. Radvan
- 520 9_
- $a BACKGROUND/AIMS: Recent studies demonstrated that extravascular lung water (EVLW) is a reliable and independent marker for outcome. The primary therapeutically goal in critically ill patients is to resuscitate and retain adequate organ perfusion by fluid administration, where is necessary to achieve adequate intravascular filling, but avoid initiation of pulmonary edema. METHODOLOGY: Patients with severe sepsis were randomly allocated to a group treated with 20% Albumin 100 ml every 12 hours (ALB; n = 30) or with 6% hydroxyethylstarch 130/0, 4 250 ml every 6 hours (HES; n = 26). Both treatments were completed by crystalloids or norephinephrin as necessary. We analyzed amount of developed EVLW, and relation with mortality, PaO2/FiO2 and alveolo-arterial oxygen difference. RESULTS: We observed significantly greater decrease of EVLW when compared with baseline during whole monitored period of 72 hours in ALB group in contrast to HES patients (p < 0.05). Despite no significant changes of EVLW in HES group, we noted improve of PaO2/FiO2 and AaDO2 in both groups. We did not observed significant difference in mortality. CONCLUSION: The present study results show can summarize that albumin reduces in a higher amount and earlier the extravascular lung water than HES, but this reduction was not associated with improvement of oxygenation functions, which was better in HES group.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a dospělí $7 D000328
- 650 02
- $a senioři $7 D000368
- 650 02
- $a senioři nad 80 let $7 D000369
- 650 02
- $a albuminy $x aplikace a dávkování $7 D000418
- 650 02
- $a kapilární permeabilita $7 D002199
- 650 02
- $a extravaskulární plicní voda $x účinky léků $7 D015633
- 650 02
- $a ženské pohlaví $7 D005260
- 650 02
- $a deriváty hydroxyethylového škrobu $x aplikace a dávkování $7 D006895
- 650 02
- $a lidé $7 D006801
- 650 02
- $a plíce $x patofyziologie $7 D008168
- 650 02
- $a mužské pohlaví $7 D008297
- 650 02
- $a lidé středního věku $7 D008875
- 650 02
- $a kyslík $x krev $7 D010100
- 650 02
- $a plicní edém $x prevence a kontrola $7 D011654
- 650 02
- $a sepse $x parazitologie $x terapie $7 D018805
- 650 02
- $a sérový albumin $x analýza $7 D012709
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Svoboda, Petr, $d 1950- $7 mzk2005269704
- 700 1_
- $a Kantorová, Ilona $7 xx0060603
- 700 1_
- $a Scheer, Peter, $d 1973- $7 xx0033760
- 700 1_
- $a Sas, Igor $7 xx0094462
- 700 1#
- $a Bíbrová, Jitka $7 xx0195385
- 700 1_
- $a Radvanová, Jana $7 xx0137564
- 700 1_
- $a Radvan, Martin $7 xx0137562
- 773 0_
- $t Hepato-Gastroenterology $p Hepatogastroenterology $g Roč. 56, č. 96 (2009), s. 1622-1628 $x 0172-6390 $w MED00002025
- 773 0_
- $p Hepatogastroenterology $g 56(96):1622-8, 2009 Nov-Dec $x 0172-6390
- 910 __
- $a ABA008 $b x $y 4 $z 0
- 990 __
- $a 20120319124550 $b ABA008
- 991 __
- $a 20140519142941 $b ABA008
- 999 __
- $a ok $b bmc $g 901967 $s 765514
- BAS __
- $a 3
- BMC __
- $a 2009 $b 56 $c 96 $d 1622-1628 $i 0172-6390 $m Hepato-gastroenterology $x MED00002025
- GRA __
- $a NR8561 $p MZ0
- LZP __
- $a 2012-1Q10/